AzTrials
AzTrials

Metastatic CancerPhase 1NCT05940844

Study of OB-002 in Patients With Refractory Metastatic Cancer

A Phase 1 study testing OB-002 in people with Metastatic Cancer and Metastatic Colorectal Cancer, run by Orion Biotechnology Polska Sp. z o.o..

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This is an open-label, non-randomized trial with OB-002 monotherapy dose escalation followed by a dose expansion in patients with metastatic colorectal, pancreatic, gastric, breast, or urothelial cancer who have progressed on two or more treatment regimens. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
OB-002
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
No sites listed yet
Study dates
Jan 2024to Aug 2025
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Written informed consent.
  • Patients at least 18 years of age on the day of providing consent.
  • Patients with accessible metastatic lesions for repetitive biopsy retrieval.
  • Patients with histologically or cytologically confirmed metastatic colorectal, pancreatic, gastric, breast, or urothelial tumors who have progressed or were intolerant after two or more regimens and for whom no standard of care or curative therapy options are available.
  • Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 within 7 days of the start of treatment
  • Patients with evaluable and measurable lesions as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Show all 17Show fewer
  • Patients with adequate organ function at the time of enrollment as defined below:
  • Neutrophil count ≥1500/mm3
  • Platelet count ≥7.5 × 105/mm3
  • Hemoglobin >9.0g/dL (transfusion >2 weeks before testing permitted)
  • Aspartate transaminase (AST), alanine transaminase (ALT)
  • ≤2.5 × the upper limit of normal (ULN) (≤5-times in patients with liver metastasis)
  • Total bilirubin ≤1.5 × ULN
  • Creatinine clearance >60 mL (determined by Cockcroft-Gault Equation)
  • International normalized ratio (INR) ≤1.5 × ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT)
  • In women with the potential for pregnancy (including patients with amenorrhea due to medical reasons, such as chemical menopause), after consenting to the study, the patient must agree to use contraception from enrollment and for at least 12 weeks after taking the final dose of the investigational drug. Women with the potential for pregnancy include those who have begun menstruation, who have not undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy, and who have not gone through menopause. Menopause is defined as the consecutive absence of menstrual periods for ≥12 months. Total abstinence is an acceptable mode of contraception.
  • In the case of men, the patient must agree after consenting to the study to use contraception from enrollment and for at least 13 weeks after taking the final dose of the investigational drug (a period of 90 days [the spermatogenesis cycle] is added to 5-times the elimination half-time of I/O agent. Total abstinence is an acceptable mode of contraception.

Who cannot join

  • Unwilling to undergo biopsy retrieval during screening (unless an archival sample taken within 3 months before screening is available) and after the fourth infusion of OB-002
  • Patients who have undergone systemic chemotherapy, radiotherapy, surgery, or hormone therapy <28 days before enrollment, also see exclusion criterion #8.
  • Note: Patients must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Patients with ≤Grade 2 neuropathy may be eligible. If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.
  • Patients with a history of CCR5 antagonist therapy (e.g., vicriviroc, maraviroc).
  • Patients with uncontrolled hypertension (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥90 mmHg) with treatment
  • QTc interval greater than 450 msec (males) or 470 msec (females)
Show all 26Show fewer
  • Patients with acute coronary syndrome (including myocardial infarction and unstable angina), and with a history of coronary angioplasty or stent placement performed within 6 months before enrollment
  • Patients with a large amount of pleural effusion or ascites requiring more than weekly drainage
  • Patients with a history of (non-infectious) pneumonitis that required steroids or have current pneumonitis.
  • Patients with a ≥Grade 3 active infection according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0
  • Patients with symptomatic brain metastasis (1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system [CNS] disease)
  • Patients with partial or complete gastrointestinal obstruction
  • Patients with interstitial lung disease requiring treatment with systemic steroids or other agents
  • Patients who test positive for either anti-human immunodeficiency virus type 1 (HIV-1) antibodies, hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (HCV) antibodies with a positive HCV RNA viral load test
  • Patients with concurrent autoimmune disease, or a history of chronic or recurrent autoimmune disease
  • Patients who require systemic corticosteroids equivalent to ≥10 mg prednisone (excluding temporary usage for tests, prophylactic administration for allergic reactions, or to alleviate swelling associated with radiotherapy) or immunosuppressants, or who have received such a therapy <14 days before enrollment in the present study
  • Patients with a history or findings of ≥Grade 3 congestive heart failure according to the New York Heart Association functional classification
  • Patients with a seizure disorder who require pharmacotherapy
  • Persistent proteinuria >3.5 g/24 hours measured by urine protein-creatinine ratio from a random urine sample (≥Grade 3, NCI CTCAE v5.0)
  • Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation
  • Major surgical procedure or significant traumatic injury within 28 days before the start of study medication
  • Non-healing wound, non-healing ulcer, or non-healing bone fracture
  • Patients with evidence or history of any bleeding diathesis, irrespective of severity
  • Any hemorrhage or bleeding event ≥Grade 3 (NCI CTCAE v 5.0) within 4 weeks prior to the start of the study medication
  • Women who are pregnant or breastfeeding, or with the potential for pregnancy unwilling to undergo contraception
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study drug

About this study

Official title: A Phase 1b, Open-label, Non-randomized Trial for the Assessment of Safety, Tolerability, and Pharmacokinetics of OB-002 as a Monotherapy in Patients With Refractory Metastatic Colorectal, Pancreatic, Gastric, Breast, or Urothelial Cancer

This is an open-label, non-randomized trial with OB-002 monotherapy dose escalation followed by a dose expansion in patients with metastatic colorectal, pancreatic, gastric, breast, or urothelial cancer who have progressed on two or more treatment regimens.

Read the detailed description

The dose escalation will use a conventional 3+3 approach, at a minimum of four planned dose levels (0.25, 0.5, 1.0, and 1.5 mg/kg), to establish a maximum tolerated dose (MTD). Additional dose levels may be investigated if PK, pharmacodynamic (PD), safety, and efficacy data indicate higher dose levels may be appropriate. The first patient - sentinel patient - at each dose level will be observed for three days before additional patients can be dosed within the same dose level.

The patients will be dosed once weekly (Days 1, 8, 15, and 22) over a 4-week treatment cycle with a 28-day dose-limiting toxicity (DLT) observation period. After a full cohort has completed Day 28 assessments there will be a pause for safety evaluation conducted by the Safety Monitoring Committee (SMC). Once safety data have been reviewed, the SMC will make their recommendations to Orion who will decide whether to proceed to dosing the next dose cohort. Screening may continue during the SMC pause.

Once all patients in the highest planned cohort (1.5 mg/kg OB 002) have completed Day 28 assessments, safety, PK, receptor occupancy (RO), and tolerability data will be reviewed to determine which dose level should be expanded or whether an additional dose level is needed. The expanded cohort will enrol 6 patients at the identified dose level.

Patients may remain on treatment until disease progression with a follow-up (FU) period of up to 12 months. All adverse events (AEs) and non-invasive tumor assessments will be documented throughout the FU period to characterize the objective response rate (ORR) and, progression-free survival (PFS). Patients that do not complete the DLT observation period for non-DLT reasons will be replaced

Being tested
OB-002
Keywords
solid tumors, CCR5
Medical subject headings
Neoplasm Metastasis, Colorectal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Breast Neoplasms, Carcinoma, Transitional Cell

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OB-002Drug

    The patients will be dosed once weekly (Days 1, 8, 15 and 22) over a 4-week treatment cycle with a 28 day dose-limiting toxicity (DLT) observation period.

Study groups in NCT05940844
Study groupRoleWhat they receive
open label OB-002 monotherapy 0.25 mg/kgExperimentalDose Level 1
Receives: Drug: OB-002
open label OB-002 monotherapy 0.5 mg/kgExperimentalDose Level 2
Receives: Drug: OB-002
open label OB-002 monotherapy 1.0 mg/kgExperimentalDose Level 3
Receives: Drug: OB-002
open label OB-002 monotherapy 1.5 mg/kgExperimentalDose Level 4
Receives: Drug: OB-002
open label OB-002 monotherapy expansion cohortExperimentalDose Expansion
Receives: Drug: OB-002

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety: adverse events

    Number of patients experiencing adverse events (AEs), serious AEs (SAEs) abnormalities in clinical laboratory tests, vital signs, electrocardiograms (ECGs), and physical exams

    Measured: From date of screening until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months

  2. Safety: Maximum Tolerated Dose

    MTD will be defined on the basis of dose-limiting toxicities (DLTs)

    Measured: From date of first infusion with 28 days observation period (+/-3 days)

Secondary outcomes (7)

  1. (PK) Pharmacokinetics Cmax

    To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with maximum observed concentration (Cmax) profile of OB-002 in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer.

    Measured: samples are collected from first to fourth infusion (period of 28 days +/- 2 days)

  2. (PK) Pharmacokinetics Tmax

    To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with time to maximum serum concentration (Tmax) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer.

    Measured: samples are collected from first to fourth infusion (period of 28 days +/- 2 days)

  3. (PK) Pharmacokinetics AUC0-t

    To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with area under the curve from time 0 to last sampling time (AUC0-t) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer.

    Measured: samples are collected from first to fourth infusion (period of 28 days +/- 2 days)

  4. (PK) Pharmacokinetics AUC0 ∞

    To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with area under the curve from time 0 to infinity (AUC0 ∞) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer.

    Measured: samples are collected from first to fourth infusion (period of 28 days +/- 2 days)

  5. (PK) Pharmacokinetics t1/2

    To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with terminal half-life (t1/2) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer.

    Measured: samples are collected from first to fourth infusion (period of 28 days +/- 2 days)

  6. (PK) Pharmacokinetics Vd

    To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with the volume of distribution (Vd) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer.

    Measured: samples are collected from first to fourth infusion (period of 28 days +/- 2 days)

  7. (PK) Pharmacokinetics CL

    To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with clearance (CL) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer.

    Measured: samples are collected from first to fourth infusion (period of 28 days +/- 2 days)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jul 2023
  2. Study startJan 2024 (estimated)
  3. Primary completionApr 2025 (estimated)
  4. Study completionAug 2025 (estimated)

Why it stopped: study terminated due to changes in the drug development plan

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Sequential
Model description
A total of up to 36 patients will be screened and 18 enrolled. At least 3 patients at each of the 4 dose levels (0.25, 0.5, 1.0, and 1.5 mg/kg planned) and up to 6 patients at the highest dose(s) if no MTD. An additional 3 patients may be recruited at any of the dose levels to define the dose(s) for further development. Each patient will be enrolled for at least one 28-day cycle of treatment with a FU period of up to 12 months.
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05940844
Sponsor's protocol ID
OB-002-101
Status last verified
Jul 2023
First submitted
16 Jun 2023
Last updated
9 Apr 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing OB-002 in people with Metastatic Cancer and Metastatic Colorectal Cancer, run by Orion Biotechnology Polska Sp. z o.o..

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 17 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 9 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety: adverse events (time frame: From date of screening until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05940844.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in